Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 37, 2016, Pages 10328-10333

  Flagmeier, Patrick ^a   Meisl, Georg ^a   Vendruscolo, Michele ^a   Knowles, Tuomas P J ^a   Dobson, Christopher M ^a   Buell, Alexander K ^a,b   Galvagnion, Céline ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Familial Parkinson's disease; Kinetic analysis; Lipid induced aggregation; Neurodegenerative disease; Seeded aggregation

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; LIPID; NERVE PROTEIN;

ACIDITY; AMINO ACID SUBSTITUTION; ARTICLE; CATALYSIS; CONTROLLED STUDY; FAMILIAL DISEASE; GENETIC ASSOCIATION; HUMAN; IN VITRO STUDY; PARKINSON DISEASE; PH; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; WILD TYPE; CHEMISTRY; GENETICS; KINETICS; MUTATION; PATHOLOGY; PROTEINOSIS;

ALPHA-SYNUCLEIN; AMYLOID; HUMANS; KINETICS; LIPIDS; MUTATION; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 84987620704     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1604645113     Document Type: Article

References (47)

1. Kim WS, Kågedal K, Halliday GM (2014) α-Synuclein biology in Lewy body diseases. Alzheimers Res Ther 6(5):73.
2. Nakajo S, et al. (1990) Purification and characterization of a novel brain-specific 14-kDa protein. J Neurochem 55(6):2031-2038.
3. Shibayama-Imazu T, et al. (1993) Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14). Brain Res 622(1-2):17-25.
4. Stefanis L (2012) α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med 2(2):a009399.
5. Iwai A, et al. (1995) The precursor protein of non-A β component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14(2): 467-475.
6. Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8(8):2804-2815.
7. Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11(20):2395-2407.
8. Gundelfinger ED, Kessels MM, Qualmann B (2003) Temporal and spatial coordination of exocytosis and endocytosis. Nat Rev Mol Cell Biol 4(2):127-139.
9. Atluri PP, Ryan TA (2006) The kinetics of synaptic vesicle reacidification at hippocampal nerve terminals. J Neurosci 26(8):2313-2320.
10. Sinning A, Hübner CA (2013) Minireview: pH and synaptic transmission. FEBS Lett 587(13):1923-1928.
11. Forgac M (2007) Vacuolar ATPases: Rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol 8(11):917-929.
12. Masliah E, et al. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46(6):857-868.
13. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 95(11):6469-6473.
14. Polymeropoulos MH, et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276(5321):2045-2047.
15. Krüger R, et al. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 18(2):106-108.
16. Zarranz JJ, et al. (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55(2):164-173.
17. Proukakis C, Houlden H, Schapira AH (2013) Somatic α-synuclein mutations in Parkinson's disease: Hypothesis and preliminary data. Mov Disord 28(6):705-712.
18. Lesage S, et al.; French Parkinson's Disease Genetics Study Group (2013) G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 73(4):459-471.
19. Fujioka S, et al. (2014) Update on novel familial forms of Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 20(Suppl 1):S29-S34.
20. Buell AK, et al. (2014) Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proc Natl Acad Sci USA 111(21):7671-7676.
21. Galvagnion C, et al. (2015) Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol 11(3):229-234.
22. Conway KA, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97(2):571-576.
23. Narhi L, et al. (1999) Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J Biol Chem 274(14):9843-9846.
24. Li J, Uversky VN, Fink AL (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 40(38):11604-11613.
25. Lashuel HA, et al. (2002) α-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. JMolBiol322(5):1089-1102.
26. Li J, Uversky VN, Fink AL (2002) Conformational behavior of human α-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology 23(4-5):553-567.
27. Fredenburg RA, et al. (2007) The impact of the E46K mutation on the properties of α-synuclein in its monomeric and oligomeric states. Biochemistry 46(24):7107-7118.
28. Lemkau LR, et al. (2012) Mutant protein A30P α-synuclein adopts wild-type fibril structure, despite slower fibrillation kinetics. J Biol Chem 287(14):11526-11532.
29. Ghosh D, et al. (2013) The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro. Biochemistry 52(40):6925-6927.
30. Khalaf O, et al. (2014) The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity. J Biol Chem 289(32):21856-21876.
31. Fares MB, et al. (2014) The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet 23(17):4491-4509.
32. Dobson CM (2003) Protein folding and misfolding. Nature 426(6968):884-890.
33. Knowles TP, Vendruscolo M, Dobson CM (2014) The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 15(6):384-396.
34. Cohen SI, Vendruscolo M, Dobson CM, Knowles TP (2012) From macroscopic measurements to microscopic mechanisms of protein aggregation. J Mol Biol 421(2-3): 160-171.
35. Grey M, et al. (2015) Acceleration of α-synuclein aggregation by exosomes. J Biol Chem 290(5):2969-2982.
36. Vácha R, Linse S, Lund M (2014) Surface effects on aggregation kinetics of amyloidogenic peptides. J Am Chem Soc 136(33):11776-11782.
37. Grey M, Linse S, Nilsson H, Brundin P, Sparr E (2011) Membrane interaction of α-synuclein in different aggregation states. J Parkinsons Dis 1(4):359-371.
38. Galvagnion C, et al. (2016) Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein. Proc Natl Acad Sci USA 113(26): 7065-7070.
39. Wood SJ, et al. (1999) α-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274(28):19509-19512.
40. Clayton DF, George JM (1998) The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21(6):249-254.
41. Bonini NM, Giasson BI (2005) Snaring the function of α-synuclein. Cell 123(3):359-361.
42. Fusco G, et al. (2014) Direct observation of the three regions in α-synuclein that determine its membrane-bound behaviour. Nat Commun 5:3827.
43. Meisl G, et al. (2014) Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides. Proc Natl Acad Sci USA 111(26): 9384-9389.
44. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M (2002) Biochemical characterization of the core structure of α-synuclein filaments. J Biol Chem 277(21):19213-19219.
45. Vilar M, et al. (2008) The fold of α-synuclein fibrils. Proc Natl Acad Sci USA 105(25): 8637-8642.
46. Knowles TP, et al. (2009) An analytical solution to the kinetics of breakable filament assembly. Science 326(5959):1533-1537.
47. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305(5688):1292-1295.